{
    "organizations": [],
    "uuid": "662e1b86c622edd1eceed7fb8d641d92ca9cce99",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-receives-fast-track-designat/brief-merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-idUSFWN1R90KJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Merck & Co Inc:\n* MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN\n* MERCK & CO INC - ‍SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS​\n* MERCK & CO INC - ‍JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T20:43:00.000+03:00",
    "crawled": "2018-03-28T19:21:50.044+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "receives",
        "designation",
        "tepotinib",
        "cell",
        "lung",
        "cancer",
        "japan",
        "merck",
        "co",
        "inc",
        "designation",
        "encompasses",
        "possibility",
        "target",
        "review",
        "period",
        "merck",
        "co",
        "inc",
        "ministry",
        "health",
        "labour",
        "welfare",
        "grant",
        "sakigake",
        "designation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}